BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+13.81%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.53B
AUM Growth
+$7.53B
(+8.1%)
Cap. Flow
-$9.29M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13
Top Buys
| 1 |
Incyte
INCY
|
$17.1M |
| 2 |
Intuitive Surgical
ISRG
|
$15.7M |
| 3 |
DexCom
DXCM
|
$14.5M |
| 4 |
Centene
CNC
|
$13.5M |
| 5 |
Abbott
ABT
|
$12.6M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$40.9M |
| 2 |
UnitedHealth
UNH
|
$38.4M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$32.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
Molina Healthcare
MOH
|
$18M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $368M | 4.88% | 9,743,900 +280,500 | +3% | +$10.6M |
|
2
argenx
ARGX
$43.6B
| $345M | 4.58% | 911,100 -8,246 | -0.9% | -$3.12M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $331M | 4.4% | 2,773,294 -81,852 | -3% | -$9.78M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $317M | 4.2% | 1,096,028 -62,098 | -5% | -$17.9M |
|
5
Moderna
MRNA
$9.37B
| $284M | 3.77% | 1,582,328 +22,527 | +1% | +$4.05M |
|
|
6
Intuitive Surgical
ISRG
$170B
| $254M | 3.37% | 957,086 +58,994 | +7% | +$15.7M |
|
|
7
Incyte
INCY
$16.5B
| $238M | 3.15% | 2,956,977 +212,700 | +8% | +$17.1M |
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $219M | 2.91% | 921,213 -35,549 | -4% | -$8.45M |
|
|
9
Abbott
ABT
$231B
| $185M | 2.45% | 1,684,479 +114,628 | +7% | +$12.6M |
|
10
Boston Scientific
BSX
$156B
| $181M | 2.4% | 3,902,924 +98,877 | +3% | +$4.58M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $177M | 2.35% | 3,342,236 +12,957 | +0.4% | +$686K |
|
|
MYOV
12
DELISTED
Myovant Sciences Ltd.
MYOV
| $159M | 2.11% | 5,910,639 -2,000 | -0% | -$53.9K |
|
13
Jazz Pharmaceuticals
JAZZ
$7.75B
| $121M | 1.6% | 756,636 -67,203 | -8% | -$10.7M |
|
14
Stryker
SYK
$150B
| $120M | 1.6% | 492,234 +15,302 | +3% | +$3.74M |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $119M | 1.58% | 1,906,461 -286,739 | -13% | -$17.9M |
|
|
16
UnitedHealth
UNH
$281B
| $119M | 1.58% | 224,294 -72,460 | -24% | -$38.4M |
|
17
Revolution Medicines
RVMD
$7.1B
| $116M | 1.53% | 4,855,162 +175,000 | +4% | +$4.17M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $114M | 1.51% | 4,056,792 -2,000 | -0% | -$56.2K |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $113M | 1.5% | 2,969,278 -1,400 | -0% | -$53.4K |
|
|
20
DexCom
DXCM
$29.5B
| $112M | 1.49% | 988,476 +128,016 | +15% | +$14.5M |
|
21
Insulet
PODD
$23.9B
| $102M | 1.35% | 345,780 -28,173 | -8% | -$8.29M |
|
22
Inspire Medical Systems
INSP
$2.77B
| $101M | 1.34% | 401,742 -26 | -0% | -$6.55K |
|
23
Danaher
DHR
$147B
| $97.2M | 1.29% | 366,350 -1,085 | -0.3% | -$288K |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $89.8M | 1.19% | 693,209 -62,689 | -8% | -$8.12M |
|
25
Becton Dickinson
BDX
$55.3B
| $84.3M | 1.12% | 331,560 -3,278 | -1% | -$834K |
|